Please assess the completion status of the following clinical trial:

Trial Title: Trial of Doxycycline to Reduce Sputum MMP-9 Activity in Adult Cystic Fibrosis (CF) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cystic Fibrosis~* Hospitalization for Pulmonary exacerbation~Exclusion Criteria:~* Significant GI illness~* Participation in another Investigational Protocol~* Allergies to Doxycycline~* Sputum Culture only positive for Staphylococcus aureus,~* Pregnant or Nursing~* Unwilling to use effective birth control~* Elevated LFT's greater than 3x the upper limit of normal~* Creatinine greater than 1.5x the upper limit of normal~* Lung transplantation~* Substance abuse within 30 days of screening

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation
- doxycycline (Type: ACTIVE_COMPARATOR): Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation

Based on this trial design, predict the completion outcome and termination type (if applicable).